产品优势

（1）无血清、无动物源成分、化学成分明确；

（2）自主化、国产化的原研体系;供货稳定，高性价比;

（3）支持临床级/药品级细胞培养，培养的iPSC细胞通过了中国食品药品检定研究院质量复核；iPSC来源功能药物通过了IND默示许可。

产品规格

细胞形态与生长情况

文献引用

Establishment of an induced pluripotent stem cell line from a patient with hereditary transthyretin amyloidosis carrying transthyretin (TTR) mutation p.Phe53Val

2020. He Shan, et al. Stem Cell Research(IF 1.587).

Establishment of an induced pluripotent stem cell line PUMCHi004-A from a hereditary transthyretin amyloid cardiomyopathy patient with transthyretin (TTR) p.Asp38Asn mutation

2020. He Shan , et al.  Stem Cell Research(IF 1.587).

Generation of an induced pluripotent stem cell (iPSC) line (THSJTUi001-A) from a Wilson's disease patient harboring a homozygous Arg778Leu mutation in ATP7B gene

2020. Wang, Shu Hong , et al. Stem Cell Research(IF 1.587).

更多文献引用，请拨打021-61283010详细咨询